Discovery of dopamine deficiency and the possibility of dopa therapy in Parkinsonism

  • T. Nakajima
Part of the Key Topics in Brain Research book series (KEYTOPICS)


The particulars regarding the discovery of dopamine deficency in Parkinson’s disease and its neurochemical background are described historically. Furthermore, the novel idea of dopa administration for treatment of the disease and syndrome and its first clinical trial are also introduced.


Globus Pallidus Subcortical Nucleus Dopamine Deficiency Japan Medical Extrapyramidal System 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Birkmayer WZ, Hornykiewicz O (I960) Der 3,4-L-Dioxyphenylalanin (= DOPA)-Effekt bei der Parkinson-Akinese. Wien Klin Wschr 73: 787–788Google Scholar
  2. Carlsson A, Lindvist M, Magnusson T, Waldeck B (1958) On the presence of 3-hydroxytyramine in brain. Science 127: 471PubMedCrossRefGoogle Scholar
  3. Carlsson A (1959) The occurrence, distribution and physiological role of catecholamines in the nervous system. Pharmacol Rev 11: 490–493PubMedGoogle Scholar
  4. Ehringer H, Hornykiewicz O (I960) Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im Gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Klin Wschr 38: 1236–1240Google Scholar
  5. Greenfield JG (1955) James Parkinson 1755–1824. In: Critchley M (ed) A bicentenary volume of papers dealing with Parkinson’s disease. Macmillan, New York, p 219Google Scholar
  6. Parkinson J (1817) An essay of the shaking palsy. Whittingham and Rowland, LondonGoogle Scholar
  7. Sano I (1959) Biochemical studies of aromatic monoamines in the brain. In: Japanese Medicine in 1959. The report of scientific meetings in the 15th General Assembly of the Japan Medical Congress, vol V, pp 607–615Google Scholar
  8. Sano I, Kakimoto Y, Taniguchi K, Takesada M, Gamo J, Nishinuma K (1959) Distribution of catechol compounds in human brain. Biochim Biophys Acta 32: 586–587PubMedCrossRefGoogle Scholar
  9. Sano I (I960) Biochemistry of extrapyramidal motor system. Shinkei Kenkyu no Shinpo (Adv Neurol Sci) 5:42–48Google Scholar
  10. Sano I, Taniguchi K, Gamo T, Takesada M, Kakimoto Y (I960) Die Katechinamine im Zentralnervensystem. Klin Wschr 38: 57–62Google Scholar
  11. Vogt M (1954) The concentration of sympathin in different parts of the central nervous system under normal conditions and after the administration of drugs. J Physiol 123: 451–458PubMedGoogle Scholar
  12. Von Euler US (1946) A specific sympathomimetic ergone in adrenergic nerve fibers (sympathin) and its relations to adrenaline and noradrenaline. Acta Physiol Scand 12: 73–97CrossRefGoogle Scholar

Copyright information

© Springer-Verlag/Wien 1991

Authors and Affiliations

  • T. Nakajima
    • 1
  1. 1.Department of NeuropsychiatryKyoto Prefectural University of MedicineKamigyoku, Kyoto 602Japan

Personalised recommendations